Teva Pharmaceutical on Thursday announced the launch of generic Baraclude (entecavir) tablets in 0.5-mg and 1-mg dosage strengths. The company was the first to file, giving it 180 days of marketing exclusivity for the drug.
Teva Pharmaceutical Industries on Thursday announced that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb's entecavir compound claim of U.S. Patent No. 5,206,244 invalid.
The Food and Drug Administration has given tentative approval to a generic drug for HIV/AIDS made by Mylan subsidiary Matrix Labs for distribution in developing countries under the President’s Emergency Plan for AIDS Relief, Mylan said Tuesday.